PL3580333T3 - Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku - Google Patents

Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku

Info

Publication number
PL3580333T3
PL3580333T3 PL18706096T PL18706096T PL3580333T3 PL 3580333 T3 PL3580333 T3 PL 3580333T3 PL 18706096 T PL18706096 T PL 18706096T PL 18706096 T PL18706096 T PL 18706096T PL 3580333 T3 PL3580333 T3 PL 3580333T3
Authority
PL
Poland
Prior art keywords
migration
assay
high throughput
immune cell
tumor cytotoxicity
Prior art date
Application number
PL18706096T
Other languages
English (en)
Inventor
Hilary A. SHERMAN
Original Assignee
Corning Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corning Incorporated filed Critical Corning Incorporated
Publication of PL3580333T3 publication Critical patent/PL3580333T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/21Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/28Vascular endothelial cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/003D culture
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18706096T 2017-02-07 2018-02-06 Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku PL3580333T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455881P 2017-02-07 2017-02-07
PCT/US2018/017081 WO2018148208A1 (en) 2017-02-07 2018-02-06 A high throughput 3d assay for immune cell and drug homing, migration and tumor cytotoxicity
EP18706096.7A EP3580333B1 (en) 2017-02-07 2018-02-06 A high throughput 3d assay for immune cell and drug homing, migration and tumor cytotoxicity

Publications (1)

Publication Number Publication Date
PL3580333T3 true PL3580333T3 (pl) 2021-08-02

Family

ID=61244768

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18706096T PL3580333T3 (pl) 2017-02-07 2018-02-06 Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku

Country Status (8)

Country Link
US (1) US10859565B2 (pl)
EP (1) EP3580333B1 (pl)
JP (1) JP7242536B2 (pl)
CN (1) CN110312791A (pl)
CA (1) CA3052970A1 (pl)
PL (1) PL3580333T3 (pl)
SG (1) SG11201907277XA (pl)
WO (1) WO2018148208A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022177250A2 (ko) * 2021-02-16 2022-08-25 연세대학교 산학협력단 고순도의 암 오가노이드, 및 이의 제조방법
US20240269678A1 (en) * 2021-06-07 2024-08-15 Plexium, Inc. Transfer dispensers for assay devices with bead size exclusion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090094814A (ko) * 2006-10-10 2009-09-08 스퀴코어 암의 치료 및 진단을 위한 조성물 및 방법
WO2009126524A2 (en) * 2008-04-08 2009-10-15 Massachusetts Institute Of Technology Three-dimensional microfluidic platforms and methods of use thereof
US8163537B2 (en) * 2009-01-27 2012-04-24 Corning Incorporated Nested permeable support device and method for using the nested permeable support device
US9790465B2 (en) * 2013-04-30 2017-10-17 Corning Incorporated Spheroid cell culture well article and methods thereof
JP6832042B2 (ja) * 2014-10-29 2021-02-24 コーニング インコーポレイテッド スフェロイド捕捉用挿入体

Also Published As

Publication number Publication date
US10859565B2 (en) 2020-12-08
SG11201907277XA (en) 2019-09-27
WO2018148208A1 (en) 2018-08-16
CN110312791A (zh) 2019-10-08
JP7242536B2 (ja) 2023-03-20
JP2020510414A (ja) 2020-04-09
CA3052970A1 (en) 2018-08-16
US20180224428A1 (en) 2018-08-09
EP3580333B1 (en) 2021-04-21
EP3580333A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
IL265309A (en) Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
ZA201705923B (en) Drug conjugates comprising antibodies against claudin 18.2
IL267129A (en) New T-cell receptors and immunotherapy using them
PT3347379T (pt) Anticorpos anti-tígitos, anticorpos anti-pvrig e as suas combinações
ZA202102745B (en) Anti-ptk7 immune cell cancer therapy
ZA202102740B (en) Anti-liv1 immune cell cancer therapy
ZA201900664B (en) T cell receptors and immune therapy using the same
EP3112378A4 (en) Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
IL257956A (en) New carbohydrate antibodies, pharmaceutical preparations and their uses
IL268244A (en) Methods, arrays and their uses
GB201713653D0 (en) Dosage regimen
IL257434A (en) Mrka polypeptides, antibodies, and uses thereof
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
PL3580333T3 (pl) Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku
EP3215193A4 (en) Dosage regimen for pegylated interferon
SG11202000811RA (en) Methods for activating immune cells
PL3541911T3 (pl) Preparaty, ich wytwarzanie i zastosowanie
HUE047919T2 (hu) Biológiai asszimilációra alkalmas proteo-melanisztikus komplex, készítmény és felhasználásai
SI3500593T1 (sl) T-celični receptorji in imunska terapija z njihovo uporabo
IL261539A (en) Multi-drug composition, methods and uses
IL267131A (en) Novel t cell receptors and immune therapy using the same
HK40061080A (en) Anti-ptk7 immune cell cancer therapy
HK40060689A (en) Anti-liv1 immune cell cancer therapy
HK40034991A (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof